Ramon.Space builds space resilient super-computing systems that revolutionize the way software is written, applied, and processed in space.

 

Article published at www.jpost.com on May 25, 2021.

 

The Ramon.Space team. (photo credit: Courtesy)The Ramon.Space team. (photo credit: Courtesy)

Yokneam-based space computing solutions company Ramon.Space said Tuesday it raised $17.5 million in Series A funding.

The capital will be used to continue development of the company’s computing solutions, support its rapidly expanding US and Israel operations, and expand the team globally, the company said. The round includes StageOne Ventures, Deep Insight, WorldQuant Ventures, UMC Capital and existing investor Grove Ventures.

Ramon.Space builds space resilient super-computing systems that revolutionize the way software is written, applied, and processed in space. The use of software in space has been limited because the hardware needed to support it could not function in such harsh conditions. Ramon.Space aims to transform the way software and hardware are used in space so applications can be developed, updated and adapted in real-time, creating infinite possibilities for new space satellite payloads and deep space missions.

The company’s technology is already deployed in space and used in many satellites and more than 50 space missions across the solar system, with zero failures, the company said.

In March, the company’s supercomputers were deployed in autonomous satellites developed as part of Technion-Israel Institute of Technology’s Adelis-SAMSON project, which were launched from Kazakhstan and will be used to calculate the location of planes, ships and people.

“Ramon.Space technology will play a disruptive and revolutionary role in solving some of the key challenges in this industry,” said Barak Ben-Eliezer, Managing Partner at Deep Insight. “Their innovation has helped accelerate new space intelligent systems and data processing within a $350 billion space industry expected to grow to more than $1 trillion.”

Ramon.Space is named after Israel’s first astronaut Ilan Ramon, who died in 2003 when his space shuttle burnt up as it reentered Earth’s atmosphere.

Sharp rise is due to increase in later-stage funding rounds and is indication that ecosystem is maturing, Start-Up Nation Central study says

 

Article published at www.timesofisrael.com on May 30, 2021.

 

Illustrative image of a doctor with digital icons (chaiyapruek2520, iStock by Getty Images)Illustrative image of a doctor with digital icons (chaiyapruek2520, iStock by Getty Images)

Israeli companies in the digital health sector raised some $700 million during the first quarter of 2021, almost matching the amount raised by startups in the field in the whole of 2020, new data by Start-Up Nation Central, a nonprofit that tracks the nation’s tech industry, shows.

“As the investment world and the healthcare industry begin to look beyond the COVID-19 pandemic,” they set their sights on Israel, the so-called Startup Nation “and the incredible innovation taking place in the local health-tech scene, particularly in the fields of deep tech and AI that are game-changers when it comes to decision support, diagnostics, and clinical workflow management,” the nonprofit said in a blogpost last week, based on research conducted by its analyst Lena Rogovin.

The main reason for this quarter’s uptick — the sum is equal to 85% of all of the funding raised by the sector in 2020 — is an increase in the later-stage funding rounds, SNC said.

Out of the 31 funding rounds that were completed in Q1 this year, 17 were B rounds or later rounds, compared to a total of only 21 later-stage rounds in 2020.

The median funding amount raised in 2021 more than doubled that of the previous year, “climbing from $6 million to an astounding $14 million, a sign that the ecosystem is maturing and investors are recognizing the opportunities in growth companies,” the blogpost said.

Investments in the sector increased across the board, with a “slight advantage” for companies in the diagnostics, decision support and remote monitoring fields, the blogpost said.

The five startups that raised the most funds in the first quarter of the year were diagnostic firm K Health, a developer of an AI-based personal health assistant, which raised $132 million in a round E at a $1.4 billion valuation in January, marking the first mega round raised — over $100 million — in the Israeli digital health sector.

C2i Genomics, a developer of a liquid biopsy for cancer tumor monitoring, became the second mega-round digital health startup, raising $100 million in the quarter; Viz.ai, a developer of AI-powered stroke care technology, raised $71 million; Tyto Care, which developed a handheld device for on-demand remote medical exams, raised $50 million; and Ibex Medical Analytics, a developer of cancer diagnostic software for use by pathologists, raised $38 million.

“The strong start to 2021 shows that Israel has a lot to offer both in terms of the post-corona reality and for other areas of digital health which were less of a focus for investors in 2020, but remain essential for global healthcare industry transformation in the longer term. As the healthcare situation returns to normal, interest is starting to shift back to other parts of the sector that were a lower priority during the height of the pandemic,” wrote Rogovin, the report’s author.

“The companies that are receiving the most attention are those associated with deep-tech and artificial intelligence and we anticipate that they will remain the core technologies going forward in 2021 with an emphasis on decision support and clinical workflow management,” she added.

The digital health sector surged globally in the first quarter of the year with $8.5 billion invested in startups, vs $5.3 billion in Q1 a year earlier, according to Start-up Health, as the coronavirus pandemic highlighted how much remote care and telehealth are becoming the new normal.

A group of 20 Israeli mobility companies has joined up with government-owned transportation firms, authorities, municipalities and universities to form a private-public consortium that will tackle traffic congestion, road accidents and safety, and air pollution across Israel.

 

Article published at www.nocamels.com on May 24, 2021.

 

Israeli road traffic. Photo by Raimond Klavins on UnsplashIsraeli road traffic. Photo by Raimond Klavins on Unsplash

A group of 20 Israeli mobility companies has joined up with government-owned transportation firms, authorities, municipalities and universities to form a private-public consortium that will tackle traffic congestion, road accidents and safety, and air pollution across Israel.

The consortium participants will share anonymized data collected from users to develop new models for reducing traffic and crashes via a technological platform developed by the Israel Smart Mobility Living Lab (ISMLL), a newly launched NGO that aims to accelerate transportation innovation on a national level. The organization says its mission is to facilitate collaboration between parties for data- and technology-based countrywide projects, according to an announcement this month.

SEE ALSO: Israeli Startup Waycare Taps AI To Increase Traffic Safety, Reduce Time On Roads

The ISMLL recently received a $1 million investment by the Israel Innovation Authority and the Fuel Choices and Smart Mobility Initiative, a national program driven by 10 government ministries (Energy, Transport, Economy, Environmental Protection, Science, Finance, Defense, Agriculture, Foreign Affairs) and led by the Prime Minister’s Office.

The Israel Smart Mobility Living Lab was founded by Dr. Smadar Itskovich, who led the Division for Industrial Development in Ashdod Municipality and the Ashdod Smart Mobility Living Lab, which she later expanded into the Israel Smart Mobility Living Lab; Itshak Turgeman, an executive who has led a number of educational initiatives over the past decade including as general director of the Rashi Foundation; and Eran Shir, the co-founder and CEO of AI road safety company Nexar who also serves as the Consortium Chairman.

Ayalon highway traffic in Tel Aviv, May 2017. Deposit PhotosAyalon highway traffic in Tel Aviv, May 2017. Deposit Photos

The lab is based on the concept of the Trust::Data Alliance developed by MIT Professor Alex “Sandy” Pentland, a leading computational scientist and serial entrepreneur who also serves as a member of the ISMLL advisory board. This alliance’s mission is to create open-source tools and services that foster the development of a secure internet-based network of trusted data. It works to build new models “for digital identity, data provenance, universal access, and secure privacy-preserving transactions to harness the future potential of global data sharing.”

The unique public-private cooperation, the ISMLL indicated in a statement, can be used by transportation companies, governments and municipalities to address local and national transportation challenges by integrating data-driven sources such as traffic cameras, logs, and app usage information, while also providing R&D opportunities in real-world environments and facilitating interactions for a greater social good.

Nexar is one of the 20 companies in the ISMLL consortium, as is transportation data firm Moovit (acquired by Intel last year), traffic management company Waycare, smart road startup NoTraffic, simulation company Cognata, and autonomous robot company Blue White Robotics. among many others.

Participants also include Clal insurance, a major Israeli insurance firm, as well as Japanese insurance company Sompo, the municipalities of Ashdod, Tel Aviv, and Karlsruhe in Germany, academic institutions such as MIT, the Karlsruhe Institute of Technology (KIT), and the non-profit research center for applied computer science the Forschungszentrum Informatik (FZI), also in Karlsruhe; government-owned companies such as Netivei Israel and Elta, the Israel National Road Safety Authority.

“The technological infrastructure that we launched will enable partnership and collaboration in national projects. Tech companies will give other companies and government-owned companies access to their data, under their control, to face challenges like reducing car accidents and traffic congestion,” said Dr. Itskovich in the announcement.

“We believe that Israel’s complex transportation challenges and advanced AI technological skills will turn it into an international innovation hub,” she added.

Aviv Zeevi, the head of the Technological Infrastructure Division at the Israel Innovation Authority said that the project was launched “to accelerate innovation and solve technological challenges in Israel and around the world by using AI to get practical insights from data and cultivating collaboration between tech companies.”

The Nexar app and dashcam. Screenshot from a Nexar video on YouTube.The Nexar app and dashcam. Screenshot from a Nexar video on YouTube.

“The goal is to strengthen and improve Israel’s competitive smart and autonomous mobility industries. The collaboration of so many government-owned companies and tech companies is heartwarming and shows the need for this platform and the great spirit of Israeli companies, who love to join the national effort to face challenges, especially using advanced technology.”

The launch of the project was officially announced last week at the 9th EcoMotion Conference, an event focused on innovation in the transportation and mobility sector. EcoMotion is a joint venture of the Israeli Innovation Institute, the Smart Mobility Initiative (in the Prime Minister’s Office) and the Ministry of Economy and Industry.

Israel’s traffic problem

Traffic congestion is a major problem in Israel and is likely to get much worse, according to a 2019 OECD report. A small country with a population of some nine million people, Israel has the highest road congestion of any OECD country by a wide margin as transportation is largely based on the use of private cars, which creates massive traffic jams particularly in the center – Israel’s economic hub.

The share of travelers using public transportation is relatively low in metropolitan areas — around 20 percent — and is declining “as a result of poor service quality and rising incomes,” reads the OECD report “Assessing incentives to reduce congestion in Israel.”

According to a separate OECD report, Israel’s costs of congestion are estimated at around two percent of GDP, “above levels in other high-income economies.”

Traffic on Hashalom road in Tel Aviv, Israel. Photo by juliana souza on UnsplashTraffic on Hashalom road in Tel Aviv, Israel. Photo by juliana souza on Unsplash

A 2019 study titled “Traffic congestion on Israeli roads: faulty public policy or preordained?” suggests that Israel’s high traffic congestion stems from public policy based on the short-term perspectives as well as the political and personal interests of policymakers. “While the government has been allocating increasing funds in recent years to developing a public transportation infrastructure, it has also committed enormous sums to developing road infrastructure, higher than those devoted to public transportation. In addition, the share of taxation from motor vehicles has grown substantially, reinforcing the government’s incentive to sustain the increase in the number of vehicles,” reads the abstract.

According to a 2014 study by the Knesset Research and Information Center, the public transit infrastructure lags behind other developed countries in the OECD by about 25 years.

Through the congestion was alleviated briefly during the COVID-19 pandemic in 2020 and 2021 due to lockdowns and restrictions, the traffic problem has roared back as the government began rolling back almost all measures earlier this year because of falling infections and death rates.

Solar panels either use photovoltaic cells or photoelectrochemical cells to function and photoelectrochemical cells can only generate energy during sunlight hours.

 

Article published at www.jpost.com on May 28, 2021.

 

Solar panels at one of the projects of Enlight Renewable Energy (photo credit: RACHAF PRO DRONE)Solar panels at one of the projects of Enlight Renewable Energy (photo credit: RACHAF PRO DRONE)

Scientists in Israel have made a breakthrough in the field of solar energy, potentially leading to making the alternative energy form more efficient and productive in future use.
Researchers, led by Professor Avner Rothschild of the Department of Materials Science and Engineering at Technion, in partnership with scientists from Ben-Gurion University of the Negev and Helmholtz-Zentrum Berlin have developed advances in the understanding of how semiconductors work.

Solar panels either use photovoltaic cells or photoelectrochemical cells to function. Photoelectrochemical cells can only generate energy during sunlight hours and require external batteries to maintain energy during the night.

On the other hand, photovoltaic cells do not need external batteries but use semiconductors instead.
Semiconductors enable light energy to split water molecules into oxygen and hydrogen, which are then stored as a separate fuel source for later. Hematite, the most common material that is used as a semiconductor, suffers from a lack of efficiency, which leads to a huge waste in potential energy.

Rothschild’s team developed a new technique for testing the efficiency of hematite and other semiconductor materials, which will hopefully in the future allow for more effective solar panels to be developed.

Alan Aziz, CEO of Technion UK, said, “Reducing our use of fossil fuels is the single most important challenge our planet faces, and the answer has to be using the free energy that is all around us. Improving solar panels is just another bright idea to emerge from Technion scientists.”

Solar power is one of the major sources of renewable energy for the future, with solar panels converting the Sun’s light rays into electricity. Some sources estimate that the amount of sunlight that hits the Earth in just an hour and a half is enough to cover our global energy consumption for an entire year.

The lab has previously engineered biological sensors capable of recognizing the presence of arsenic and other poisons in water, or the presence of blood in urine.

 

Article published at www.jpost.com on May 29, 2021.

 

L-R: Assistant Professor Ramez Daniel and Dr. Ximing Li (photo credit: RAMI SHLUSH / TECHNION)L-R: Assistant Professor Ramez Daniel and Dr. Ximing Li (photo credit: RAMI SHLUSH / TECHNION)

A team of scientists from the Technion-Israel Institute of Technology in Haifa has taught colonies of Escherichia coli (E. coli) bacteria to recognize and respond to certain geometric patterns, such as letters.

The study, led by Dr. Ximing Li and Assistant Prof. Ramez Daniel, was published earlier this week in the scientific journal Nature Communications.
Daniel’s lab work is in the field of synthetic biology, specifically in the generation of biological circuits that in essence create living computers, or very primitive brains.
The lab utilizes a known scientific phenomenon called “quorum sensing.” Colonies of certain microbes are naturally capable of communicating within the colony and microbes can respond differently when alone, as opposed to when they are in a colony.

This phenomenon can be seen occurring naturally within our own bodies, every time an infection causes multiple cell types within our immune system to react in order to protect the organism.
By engineering cells to perform certain function types, one can cause individual cells to be turned on and off and perform a function – for example, fluorescence.
Using this technique, the lab has previously engineered biological sensors capable of recognizing the presence of arsenic and other poisons in water, or the presence of blood in urine.
By combining their cell engineering skills with the quorum sensing properties of the E. Coli bacteria colonies, the scientists were able, for the first time, to create an artificial neural network (ANN) capable of performing the relatively complex task of geometric-pattern recognition.

According to the researchers, the study’s results are a proof of concept for what ANNs can do.
“For example, the framework and algorithm in our study can be used to facilitate the design of living therapeutics, such as targeted drug release systems based on engineered probiotic bacteria systems,” the researchers said.

“Our proposed system can also be potentially extended to engineer inter-cellular communications in yeast cells and mammalian cells,” the researchers stated. “For the latter in particular, engineering how tissue cells contact each other would enable new applications for programming tissue development, growth and repair.

Israeli-Arab researcher at the Technion in Haifa discovers that nano-sized baking soda placed near a tumor improves the cancer treatment, especially in breast cancer.

 

Article published at www.unitedwithisrael.org on May 30, 2021.

 

Dra. Hanan Abumanhal del Technion (Technion)Dra. Hanan Abumanhal del Technion (Technion)

Baking soda, the simple household product familiar to everybody, may revolutionize the treatment of breast cancer, researchers at Israel’s Technion Institute have discovered.

A graduate research student at the Technion Institute has found a revolutionary solution for the treatment of breast cancer, showing that sodium bicarbonate – baking soda – can increase the effectiveness of chemotherapy treatment because this natural substance changes the acidity of the cancerous tumor and thus increases the effectiveness of chemotherapy.

“Many studies show and emphasize the importance of the environment of the tumor in supporting cancer cells and the ability of the cells to penetrate nearby tissues and send metastases to other organs of the body,” explained Dr. Hanan Abumanhal, a resident of northern Israel who got her PhD degree last week at the prestigious institution.

Dr. Abumanhal knew that environmental changes in the cancerous tumor tissue can affect the response of cells to treatments and encourage the development of resistance to anti-cancer treatment.

“That is why it is important to develop a synergistic treatment that changes the entire environmental balance and thus ‘suffocate’ the tumor,” she explained.

Dr. Abumanhal focused on a particularly aggressive version of breast cancer, a version created from a combination of mutations and therefore relatively resistant to existing treatments. She developed nano-particles containing baking soda (sodium bicarbonate) which can be localized on cancerous tumors.

“In this way they changed the acidity of the tissue and thus increased the penetration chemotherapeutic drugs,” she said, explaining that cancer cells are characterized by a more acidic environment than that prevailing in other body tissues.

The nano particles of baking soda reduce the acidity in the area of the tumor.

“Healthy cells also increase acidity when required for rapid energy production, but in cancer cells this is the dominant pathway for energy generation in the cell; acidity makes the cancer cells more aggressive and more metastatic,” she said. “Introducing baking soda using the method we have developed will make it possible to reduce the dose of the drug and thus reduce the side effects.”

Thus, by using a simple compound injected into the area of the tumor using very sophisticated nano-technology methods, the anti-cancer activity of chemotherapeutic drugs is enhanced and may improve treatment of the disease.

Abumanhal, from the city of Umm al-Fahm, is married to a pediatrician and the mother of two, received her doctorate at the Technion after completing her bachelor’s and master’s degree in the excellence programs in pharmaceutical sciences at the Hebrew University of Jerusalem.

In 2016, she was one of four winners of the prestigious Ariane de Rothschild four-year research scholarship, which recognizes excellence. The threshold for admission to the program is particularly high and allows doctoral students to focus on their research field.

A high magnification micrograph of cryptitis in a case of Crohn’s disease.

 

Article published at www.nocamels.com on May 2, 2021.

 

Israeli biotech company CytoReason, the developer of a computational model of the human body for faster drug discovery and development, announced a new collaboration this month with Swiss biopharmaceutical company Ferring Pharmaceuticals to establish new treatment options for patients with inflammatory bowel disease (IBD). Based in Saint-Prex, Ferring specializes in areas such as reproductive health, maternal health, gastroenterology and urology.

IBD is a chronic disease that affects the digestive system and includes Crohn’s disease and ulcerative colitis. Symptoms include abdominal pain, rectal bleeding, fatigue, and weight loss. Bouts can last for days, weeks, or sometimes months at a time.

CytoReason said in a statement that it intends to present insights on the top drug targets to provide new therapeutic options for IBD patients.

Founded in 2016 by scientists and researchers from the Technion and Stanford, CytoReason built what it has called the world’s first machine learning platform that can quantify a person’s immune system at a cellular level to better understand disease responses and treatments, and facilitate the discovery and development of more effective drugs. The simulations are applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.

“If you look at the human body, everyone is made up of the same organs,” CytoReason co-founder and CEO David Harel told NoCamels in 2019. “And every organ is made up of the same tissue. And every tissue is made up of the same cells, which are then made up of the same proteins, which are influenced by genes. Of course, the types of cells and the proportions differ and change, but in principle, it’s all the same. What we are doing at CytoReason is trying to build a computational model of human tissue, to then support clinical trials of new pharmaceuticals. That is huge!

CytoReason says its computational model of the human body simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate over time. With its proprietary database and AI-led platform, pharmaceutical and biotech companies can make data-driven decisions in a fraction of the time and cost, the company indicated.

“We are very excited to be working with the talented team at Ferring,” said Harel in a company statement .”Their expertise in gastroenterology, immunology and translational medicine will allow us to better understand the complex nature of IBD, and in turn, to create more accurate models of the disease with our AI technology. Our platform will enable Ferring to significantly shorten drug discovery time for IBD medication, dramatically reduce the costs involved, and ultimately help more patients who suffer from the chronic disease.”

CytoReason is already working with some of the world’s top 10 pharmaceutical companies including US-based multinational Pfizer, British multinational GlaxoSmithKline (gsk), and Roche, another Swiss multinational.

Science is promising us steak that’s heart-healthy, eco-friendly, and still decadent. But will we eat filet mignon from a bioreactor?

 

Article published at www.townandcountrymag.com on May 2, 2021.

 

On the third floor of a modern marble and glass building half an hour from Tel Aviv and around the corner from the Weizmann Institute of Science, Israel’s leading research institute, Neta Lavon snaps on a pair of blue latex gloves and opens an incubator. She removes a plate of six circular dishes covered with clear plastic, each containing a clear solution of vitamins, minerals, amino acids, and all the other compounds that the cells she is working with need to grow. Lavon, 49, a biology PhD who earlier managed the human embryonic stem cell lab at Cedars-Sinai Research Center in Los Angeles, takes a seat on a rolling chair before a large box about nine feet tall, six feet wide, and two feet deep. The box has a plastic screen like the ones we have grown accustomed to seeing at banks and checkout lines; here, it covers a shelf holding vials, pipettes, and other paraphernalia of scientific labs the world over.

“When I want to give the cells fresh nutrients, I take out the used growth medium and replace it with fresh,” Lavon says. The box, called a biological safety cabinet, washes the shelf with filtered air so she can slip her hands through an opening in the screen and uncover the dishes without contaminating them with the tens of millions of microbes that float around us every minute of every day. She exchanges the growth medium before moving the re-covered plate to a microscope, where she can check on the cells’ progress.

A computer screen shows what’s under the lenses: dozens of gray-white cells, roughly triangular in shape, with black nuclei, in a gray solution. “Every 24 hours they duplicate themselves until they fill the whole surface,” Lavon says. “Then we harvest the cells—that’s the terminology we use—and expand them.”

Once enough cells have developed, they’re placed in a bioreactor, a vessel for carrying out a biological process similar to devices the pharmaceutical industry uses to manufacture vaccines. The one in Lavon’s lab, a chrome-plated cylinder about a foot tall with tubes sticking out of it, looks like a blender on life support. A motor on top mixes the cells so they replicate in suspension.

“In our pilot plant we are going to have vessels that are 1,000 or more times bigger than this one,” says Lavon. “They can grow into a big mass of cells that then we can make into the meat.”

Wait, what? Meat?

The New Butcher Case

Lavon is vice president of research and development at Aleph Farms, which in 2018 produced the first steak without the use—or, many say, abuse—of a living, breathing animal. That was a thin-cut steak—not exactly a hallmark of chefs or backyard grillmasters—but it was merely a stepping stone to Aleph’s announcement in February that it had developed a ribeye, considered by many the finest cut of beef.

Aleph is one among an expanding field of companies racing to bring to market what they would rather not be called “lab-grown meat” (they prefer “cultivated” or “slaughter-free”). Though the technology did not exist even just a few years ago, today at least 33 startups in 12 countries are producing a variety of meats—from dog food to foie gras, pork to duck, chicken nuggets to beef patties. Some are promising cultivated meat in stores next year.

33 companies currently grow meat in labs—from dog food to foie gras, pork to duck, chicken nuggets to hamburger patties.

Investment is also growing rapidly: At the end of 2019 companies had raised $166 million; early in 2020 Berkeley, California’s Memphis Meats took in $161 million on its own. (Aleph has raised $14 million from Big Food heavyweight Cargill, the Israeli Innovation Authority, and others.) Together they will be rushing into a space that environmentalists, the health-conscious, and promoters of wellness have cultivated carefully. Vegetarianism is growing, from 1 percent of the U.S. population to 6 percent in recent years, as is the “flexitarian” diet.

Animal welfare is one reason many choose vegetarianism or veganism. Others aren’t ready to take that step, but, as you’ve no doubt noticed if you’ve ever set foot inside a Whole Foods, they are willing to pay more for beef that is grass-fed—meaning no “finishing” on corn in concentrated animal feedlot operations, where close confinement provides a less than ideal lifestyle for the residents—or for eggs and chicken that are free-range, even though no regulatory standard exists for such terms.

Aleph Farms co-founder Didier Toubia holds a plate with a Aleph Farms co-founder Didier Toubia holds a plate with a “traditionally” grown steak in one hand and petri dish containing cow cells in the other. PICTURE ALLIANCE

Restaurateurs have noticed these trends. “There is no doubt that diners are increasingly interested in nonmeat offerings,” says Dan Kluger, owner of Loring Place, in Greenwich Village, and veteran of some of the country’s most lauded kitchens. “They have concerns about the environmental…” he trails off. “But protein grown in labs? I’ve just been trying to get people to eat more vegetables.”

Bill Gates, who along with Richard Branson, Cargill, and Tyson Foods was an investor in Memphis Meats’ series B round of investment, told MIT Technology Review in February that to “avoid climate disaster,” rich countries like the U.S. “should move to 100 percent synthetic beef” (which would be good for Memphis Meats, and hence good for Bill Gates). That seems unlikely, given the more than 10,000 years of raising livestock ingrained in our civilization, but cultivated meat will find a niche because the march of science has not been good for cattle producers.

ILLUSTRATION BY JOE DARROW

The first studies on the effects of cholesterol, of which there is a copious amount in beef, were published in the 1940s; by 1964 medical journals were replete with warnings, such as the one in Angiology that year that told of “considerable indications for the supposition that the risk for the development of coronary disease is enhanced by hypercholesterolemia [high cholesterol].” The American Heart Association today recommends no more than 13 grams of saturated fat per day for people watching their cholesterol intake; a single McDonald’s Quarter Pounder with Cheese contains 12.

At the same time, researchers have been painting an increasingly bleak picture of the effects on the global climate of producing meat in the conventional (whoops, Aleph prefers “traditional”) way. Livestock for beef and milk production are responsible for about 10 percent of humanity’s greenhouse gas emissions—more than two-thirds the amount produced by the transport sector. The environmental effects of raising cattle can be both direct (methane released as part of the digestive process is the second-most abundant anthropogenic greenhouse gas, after carbon dioxide, and 25 times as effective as CO2 at trapping heat) and indirect (nitrogen fertilizer that grows corn that is fed to cattle spills into waterways and flows into oceans, where the nitrogen crowds out oxygen molecules that fish need to survive. Eating beef, apparently, impedes our ability to eat fish).

And we’re going to need a lot more of both. The world’s population is expected to reach 9.8 billion by 2050, a 30 percent increase in as many years. “I don’t think we can keep producing and eating animals in this manner much longer,” says Daan Luining, founder and chief technology officer of Meatable, a cultivated meat startup in the Netherlands. “We’re going for big impact—which is what’s needed in terms of climate change, antibiotic resistance, animal welfare.”

In early 2020 Memphis Meats, just one of more than 30 international companies developing “cultivated” raised $161 million from investors.

Luining, Lavon, and their competitors hope to produce meat much more efficiently and, in the process, reap environmental benefits. The Good Food Institute, a Washington, DC–based nonprofit that advocates for a food system that’s “better for the planet, people, and animals,” claims that cultured beef will use 95 percent less land than livestock and cut climate change emissions and nutrient pollution from beef production by three-quarters and by 94 percent, respectively.

The coronavirus pandemic has brought into stark relief one more argument for advancing technology to supply our hunger for meat. The virus that causes Covid-19 is widely believed to have evolved from one that circulated for years in another mammal. As the virus replicated, mutations developed that enabled it to infect and sicken humans. Thanks to our palates, Americans don’t generally eat bats, the animals most widely suspected of harboring SARS-CoV-2’s precursor, but two other potentially fatal viruses, the influenza strains H1N1 and H5N1, have come from poultry and livestock in recent years—suggesting that more are on the way.

And if pandemics aren’t enough to convince people, maybe antibiotic resistance is. Cattle producers discovered some time ago that giving their animals antibiotics to head off any possibility of bacterial infection also causes even healthy cattle to grow faster. Today meat producers in the U.S. are the largest purchasers of antibiotics—more than the healthcare industry. Overuse of antibiotics has accelerated the evolution of bacteria that can resist them, and now around 700,000 people all around the world die every year from what should be treatable infections.

Grill Marks

In March, Aleph’s in-house chef, Amir Ilan, gave me a video cooking demonstration with one of the company’s thin-cut steaks. Dressed in an apron and standing in his kitchen in Israel, he heated a cast iron pan on a black electric range while ­sautéing shiitake mushrooms and snow peas in garlic-infused oil in another pan.

He held up to the camera a white plate that held a square piece of meat. It had less red tint and more brown overtones than a typical slab of raw flesh, but it looked steaklike nonetheless. He sprinkled it with salt and pepper and then poured some oil into the pan and waited for it to start smoking.

6% of the U.S. population now identifies as vegetarian, an increase from 1 percent just in the past few years.

At the start of the demonstration, I asked Ilan if there was anything about this meat—from the type of cells they used to grow it to how it was formed in the lab—that would make it difficult to cook. Quite the opposite, he said: “We don’t have the problem of a cow [being raised] outdoors, which can toughen the meat. We create the perfect steak in the lab from the start, according to the flavor, texture, and structure we want.”

He dropped the square onto the sizzling cast iron, then swirled the vegetables some more. Once he was happy with the steak’s color, he flipped it; then he dribbled a wine reduction onto a plate that was already decorated with sprigs of rosemary. Using tweezers, he placed the steak in the center of the dish and surrounded it with a few snow peas and shiitakes. He held up the finished arrangement, which looked very much like something that would be served at a good restaurant.

Purported benefits notwithstanding, Aleph and its competitors are going to need to overcome a lot of resistance to get Americans to replace their filets mignons and pork chops with ones grown in a bioreactor. First, the price will need to fall dramatically. Aleph says it can produce a steak for $50, but considering that Memphis Meats’ hamburger was $6,000 per pound just four years ago and steak is a lot more complicated, that quote seems suspiciously low. The FDA and the Department of Agriculture will need to approve the products in a complicated two-step process that has never been tried.

An old-school cheeseburger. DA-KUKGETTY IMAGESAn old-school cheeseburger. DA-KUKGETTY IMAGES

And then there’s the question of how fake steak will go over with the people who patronize the world’s top restaurants. “My initial impression is that this is undoubtedly good for the planet and bad for gourmands and foodies,” says the novelist Jay McInerney, who writes about food and wine (the latter for Town & Country). “It’s a noble effort, but it’s hard to imagine that, certainly in the early stages, it will be relevant to people who take food really seriously. It seems like a mass-­market product, and a tough sell for people who dine at Per Se.”

The startups will also need to allay the suspicions of what has been called the “food movement”—those who favor the artisanal and eschew the industrial. Plant-based imitation burgers such as those from Beyond Meat and Impossible Foods have faced opposition for being overly processed. Not coming from any heretofore known method of producing food, cultivated meat is likely to bear similar scrutiny.

CRISTINA PEDRAZZINI/SCIENCE PHOTO LIBRARYGETTY IMAGESCRISTINA PEDRAZZINI/SCIENCE PHOTO LIBRARYGETTY IMAGES

“We don’t need this,” says chef and author Mark Bittman, whose most recent book, Animal, Vegetable, Junk: A History of Food, from Sustainable to Suicidal, details some of the less savory trends in recent culinary habits. “We have perfectly good food out there” to replace environmentally damaging, unhealthful beef, “and it’s called plants.” To convince food movement advocates, he says, cultivated meat would need to fulfill its promises of safety and low resource use and reduce consumption of animal products, rather than merely add another option to the menu.

More than anything, though, the new companies will need to produce something that is as good as the meat you can buy in a store, or a steak you’d order at a restaurant. Suzanne Tracht, chef and owner of Los Angeles’s Jar—consistently rated among the best steakhouses in the U.S.—told me, “I have a chophouse, so I have to source and get the best. My customers are not asking, ‘Where did this piece of meat come from?’ But they do know what tastes good.”

Where’s the Beef?

Aleph’s steak grew out of a process developed at the Technion-Israel Institute of Technology by Shulamit Levenberg, an expert in biomedical engineering who hopes to cultivate from cells human tissue for transplant. She worked for years at MIT with Robert Langer, a pioneer in the field of tissue engineering, before co-founding Aleph with Didier Toubia, a life science entrepreneur.

Growing muscle tissue for human consumption is much simpler than growing it for transplant. Transplanted tissue requires functional cells, such as muscle cells that can contract. But for meat, Lavon says, “We just need the components that bring the unique taste.” A “bioprinting” technique that Levenberg helped develop enables the steak to grow three-dimensionally, with a structure similar to what is cut from a slaughtered cow, and in a single batch, with muscle, fat, and other types of tissue maturing together so they’re integrated from the outset, just as nature does it. Other companies grow different cells separately and combine them later, so all they can come up with is less refined meat, such as hamburger or chicken nuggets.

Aleph starts with a small sample from an animal (a Holstein cow, for the ribeye proto­type) acquired in a nonsurgical procedure that provides enough cells for thousands of tons of meat. These cells can grow into any type of cell: muscle, fat, skin, whatever. After all the types have been replicated in an off-the-shelf bioreactor, they are 3D-printed into the combination Aleph wants. “We are designing our meat,” Lavon says, “so we can choose the proportion of fat cells to muscle cells.” The combination is then grown in a medium Aleph developed that mimics blood serum in its composition of vitamins, amino acids, minerals, fatty acids, proteins, and sugars.

10% of humanity’s greenhouse gas emissions come from beef and milk production (more than 2/3 the amount produced by the transport sector).

Less fat means less cholesterol. More of a particular compound in the growth medium means more omega-3 polyunsaturated fatty acids, which have been shown to reduce heart attacks, particularly among people who don’t eat much fish. Luining, of Meatable, foresees a day when “you can have meats that are beneficial for certain groups—I can even imagine personalized nutrition.”

Beyond Meat and Impossible Foods, which have wowed critics and consumers with their plant-based burgers’ remarkable resemblance to the real stuff, spent years figuring out how to win over carnivores by replicating the taste, texture, and aroma of meat. One component of beef that is important to the experience of both eating and cooking it, they found, is myoglobin, a type of protein found in muscle cells. Each company needed to come up with a means of mimicking myoglobin’s function in the sensory experience of biting into a cut of beef. But Aleph, Meatable, Memphis, and the rest don’t need to replicate the ­components of meat; myoglobin—and the 1,000-plus other molecules that comprise our interaction with food from animals—is already in the product. Because the product is, biologically, meat.

Big Meat’s Big Beef

“Traditional” beef enjoys several built-in advantages that will make it difficult for lab-grown meat to replace it in shopping carts in wealthy countries, and without the early support of Americans and Europeans, it will be difficult for the fledgling industry to grow to the scale necessary for it to furnish the expected demand for meat from the developing world. First, in the U.S. the federal government leases land to ranchers to graze cattle at below-market prices. The subsidies make meat cheaper, inducing Americans to eat more of it than anyone else on earth.

Then there’s the beef lobby, which doesn’t even want cultivated beef to be called beef. Missouri and several other states have already passed legislation banning companies like Aleph from using the word. Since the United States Cattlemen’s Association’s members pay for the organization to promote “beef,” “it would seem unfair to beef producers to have this new player in the game come in to take advantage of the good nutritional reputation beef has built up,” says Maggie Nutter, a Montana rancher who chairs the association’s labeling committee.

PHOTOGRAPH TAKEN BY ALAN HOPPSGETTY IMAGESPHOTOGRAPH TAKEN BY ALAN HOPPSGETTY IMAGES

As Bittman suggests, it may come down to the environmental claims, which have been at the center of the new industry’s portrayal of itself to investors and media. “There really needs to be independent analyses normalized among different products, so consumers can have confidence that if someone wants to buy something more sustainable, it really is, on some objective level,” says Gregory Jaffe, director of the Project on Biotechnology at the Center for Science in the Public Interest, a DC-based nonprofit.

Regardless, the potential health benefits may be enough to convince some hard-core meat eaters. Suzanne Tracht notes that her restaurant in Los Angeles is “down the street from the heart clinic at Cedars-Sinai, so I think there will be people interested” in cholesterol-free beef. While she’s skeptical that cultivated meat will be as savory as the cuts she procures from small operations, she’s curious.

“I’m looking forward to trying it with the real thing, side by side,” she says.

An independent data monitoring committee has reported encouraging data from the Phase III LUNAR trial.

 

Article published at Globes.co.il on April 13, 2021.

 

Drug Development company Novocure (Nasdaq: NVCR) today announced a positive update on its phase III pivotal LUNAR trial for treating lung cancer. The company said that an independent data monitoring committee (DMC), informed it that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed, and that the trial should continue with no evidence of increased systemic toxicity.

Novocure’s share price opened 48% higher on Nasdaq today at $195, giving a market cap of $20.034 billion. Prior to today, Novocure’s share price had risen 92% over the past year, and 440% in the past three years.

The primary endpoint of the LUNAR trial is superior overall survival when patients are treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. The final analysis will also include an analysis of overall survival in the immune checkpoint inhibitor and docetaxel treatment subgroups.

Novocure CEO Asaf Danziger said, “The completion of the LUNAR interim analysis is an important milestone for Novocure. We are grateful to the DMC members for their diligence, guidance and support, and are looking forward to working closely with the FDA on amendments to the protocol given the DMC’s recommendations. Pending regulatory approval, the recommended protocol adjustments could accelerate trial completion by more than a year. We look forward to sharing final data from the LUNAR trial as quickly as possible.”

NovoCure’s technology is basically a completely new approach to treating cancer, developed by Prof. Yoram Palti, now aged 82, professor emeritus of physiology and biophysics at the Technion-Israel Institute of Technology. It consists of electric fields directed at the growth from several directions that disrupt the growth of the cancerous cells, without damaging other areas. The treatment is akin to radiation, but without the damage done by radiation to tissues that it encounters on the way to the growth. Now headquartered and registered in the US, Novocure has 200 employees in Israel.

Prof. Moshe Shoham, founder of Mazor Robotics, acquired for $1.64 billion, will speak about his new company Tamar Robotics on Monday, April 12

 

Article published at Times of Israel on April 8, 2021.

 

Every year, doctors diagnose millions of people with tumors, blood clots and other masses in their brains. In each case, doctors must weigh the benefits of surgery against possible long-term neurological damage.

“Imagine having to decide between removing someone’s tumor to give them more time to live, but in the process of that they lose their ability to speak,” says Prof. Moshe Shoham, a professor at the Technion-Israel Institute of Technology and a serial entrepreneur. “Which is really the better choice?”

To reduce dilemmas like this and shorten recovery times, Shoham’s latest startup, Tamar Robotics, is developing a surgical robot that aims to revolutionize brain surgery, finally giving doctors a safer, minimally invasive tool to remove tumors and blood clots and treat other life-threatening brain conditions that now require major surgery. “We hope we will be able to let the people suffering from these conditions get back to their lives,” Shoham says. “We believe that our robotic system can do this better than a surgeon’s free hand.”

Prof. Shoham, a global pioneer in the field, established the Kahn Medical Robotics Laboratory at the Technion, from which a string of groundbreaking and successful startups have emerged to help change the practice of modern medicine.

Companies founded or co-founded by Prof. Shoham include Mazor Robotics, a surgical robotic startup acquired by Medtronic for $1.64 billion in 2018; Diagnostic Robotics, an artificial intelligence-based triage and clinical predictions platform; and Microbot Medical, a Nasdaq-traded company.

Prof. Shoham will discuss his work and the plans for Tamar Robotics in an online event on Monday, April 12 hosted by Technion Canada and OurCrowd, the Jerusalem-based investment platform.

Tamar Robotics, based at Kibbutz Yagur near Haifa, is part of the growing field of robotic surgery, in which tiny instruments inserted through small incisions perform procedures inside the human body, often also guided by imaging and sensing technology. The technique allows for more accurate and less invasive procedures, reducing patient recovery time.

The market for surgical robots is growing by 11.4% a year and is expected to be worth $9.5 trillion by 2026, according to market research firm Mordor Intelligence. With costs falling, robotic systems are expected to become much more common in numerous types of operations, according to Mordor.

Tamar Robotics is among the first such systems being developed for brain surgery. The company began when Dr. Hadas Ziso, its co-founder and Shoham’s former graduate student at the Technion, began examining ways to make brain surgery safer.

“In brain surgery there is always the fear of damaging the surrounding healthy tissue, which can result in things like people losing their ability to talk or walk,” Shoham says. “So surgeons are always weighing whether they should operate or not operate, and it’s not easy.”

Ziso and Shoham worked for five years developing a tiny robot that could target and remove tumors and other masses from the brain while leaving healthy tissue alone, and founded Tamar Robotics to bring the system to market.

The technology, currently being tested in large animals like pigs, consists of a tiny, moving robotic needle that shoots out jets of water to destroy tumors and blood clots in the brain. The needle is inserted through a small incision in the head and surgeons then control it remotely, assisted by imaging software.

“It has sufficient freedom to tackle and treat complex tumor or blood clot shapes in challenging locations within the brain,” says CEO Noam Hassidov, explaining that the tool also includes a suction mechanism that quickly removes and evacuates the destroyed tissue. Surgeons can map out a “fly-zone,” where the needle will destroy blood clots or tumor cells, and a “no-fly zone,” where the needle will not touch or damage healthy brain tissue.

“By design, this mechanism is extremely precise,” Hassidov says.

An integrated ultrasound providing constant scanning helps guide the needle in real time. This is important because the brain constantly moves during surgery as areas of tissue are removed, making it difficult to rely on pre-operative images from MRIs and other scans.

“This way, the physician can look all around and can see right away if something moves in the brain,” Hassidov says. “We can know exactly where the target mass is at all times.”

It also measures pressure inside the skull, making sure it does not rise to dangerous levels, which can cause neurological damage.

Prof. Moshe Shoham with the Mazor Robotics system, which was sold to Medtronic for $1.64 billion (Courtesy)Prof. Moshe Shoham with the Mazor Robotics system, which was sold to Medtronic for $1.64 billion (Courtesy)

One of the main obstacles in using robotics for brain surgery is the need to develop better imaging technology to help guide robotic equipment inside the brains of patients, says Alfredo Quinones-Hinojosa, chair of the department of neurological surgery at the Mayo Clinic’s campus in Jacksonville, Florida, who has no connection to Tamar Robotics.

“Just as robotic technology is used to perform abdominal surgery, in the near future it will most likely be used to perform minimally invasive brain surgery,” Dr. Quinones-Hinojosa says. “Robots will allow us to venture deep into the brain through very small incisions.”

“The biggest challenge right now is the fact that our equipment is difficult to maneuver through small spaces,” he says.

The company is in the advanced stages of testing the system on animals. Professionals in the surgical field have said they are excited about its potential use in humans in the near future.

Tamar plans to first start human trials in patients suffering from intracranial hemorrhage, or bleeding inside the brain, an acute condition that requires emergency surgery to release pressure that builds up inside the brain and threatens long-term neurological damage.

Looking back to 2001, when he founded Mazor Robotics, one of the first companies to offer robotic systems for spinal surgery, Shoham says he expects uptake of this new tool to be quick once it is approved.

“Now surgeons are more open to robotic tools than back then,” he says. “It is now clear that if we have better and sharper tools, we can do much better and save more lives.”